Hepatic perfusion imaging: Concepts and application

Magnetic Resonance Imaging Clinics of North America

Volumn 18, Issue 3, 2010, Pages 465-475

  Haider, Masoom A ^a,b   Farhadi, Farzin A ^a   Milot, Laurent ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Cirrhosis; Dynamic contrast enhancement; Hepatocellular carcinoma; Liver; Metastases; MR imaging; Perfusion

Indexed keywords

GADOLINIUM PENTETATE; PROTEIN TYROSINE KINASE INHIBITOR;

CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; HEPATOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; KIDNEY CARCINOMA; LIVER BLOOD FLOW; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER PERFUSION; NON INVASIVE MEASUREMENT; OUTCOME ASSESSMENT; PERFUSION WEIGHTED IMAGING; PROGNOSIS; REVIEW; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

FIBROSIS; HUMANS; IMAGE ENHANCEMENT; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; NEOVASCULARIZATION, PATHOLOGIC;

EID: 78649295376     PISSN: 10649689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mric.2010.07.009     Document Type: Review

References (42)

1. De Bazelaire C., Rofsky N.M., Duhamel G., et al. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma (1). Acad Radiol 2005, 12(3):347-357.
2. Elsayes K.M., Narra V.R., Yin Y., et al. Focal hepatic lesions: diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradient-echo MR imaging. Radiographics 2005, 25(5):1299-1320.
3. Hussain H.K., Londy F.J., Francis I.R., et al. Hepatic arterial phase MR imaging with automated bolus-detection three-dimensional fast gradient-recalled-echo sequence: comparison with test-bolus method. Radiology 2003, 226(2):558-566.
4. Chiandussi L., Greco F., Sardi G., et al. Estimation of hepatic arterial and portal venous blood flow by direct catheterization of the vena porta through the umbilical cord in man. Preliminary results. Acta Hepatosplenol 1968, 15(3):166-171.
5. Richter S., Mucke I., Menger M.D., et al. Impact of intrinsic blood flow regulation in cirrhosis: maintenance of hepatic arterial buffer response. Am J Physiol Gastrointest Liver Physiol 2000, 279(2):G454-G462.
6. Gulberg V., Haag K., Rossle M., et al. Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 2002, 35(3):630-634.
7. Matsui O. Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 2004, 47(3-5):271-276.
8. Martinez-Hernandez A. The hepatic extracellular matrix. II. Electron immunohistochemical studies in rats with CCl4-induced cirrhosis. Lab Invest 1985, 53(2):166-186.
9. Brannigan M., Burns P.N., Wilson S.R. Blood flow patterns in focal liver lesions at microbubble-enhanced US. Radiographics 2004, 24(4):921-935.
10. Qi X.L., Burns P., Hong J., et al. Characterizing blood volume fraction (BVF) in a VX2 tumor. Magn Reson Imaging 2008, 26(2):206-214.
11. Quantitative Imaging Biomarkers Alliance (QIBA) RSNA Available at:, Accessed July 27, 2010. http://qibawiki.rsna.org/index.php%3Ftitle%3DMR_Acquisition_Protocols.
12. Wang H.Z., Riederer S.J., Lee J.N. Optimizing the precision in T1 relaxation estimation using limited flip angles. Magn Reson Med 1987, 5(5):399-416.
13. Treier R., Steingoetter A., Fried M., et al. Optimized and combined T1 and B1 mapping technique for fast and accurate T1 quantification in contrast-enhanced abdominal MRI. Magn Reson Med 2007, 57(3):568-576.
14. Bokacheva L., Huang A.J., Chen Q., et al. Single breath-hold T1 measurement using low flip angle TrueFISP. Magn Reson Med 2006, 55(5):1186-1190.
15. Bokacheva L., Rusinek H., Chen Q., et al. Quantitative determination of Gd-DTPA concentration in T1-weighted MR renography studies. Magn Reson Med 2007, 57(6):1012-1018.
16. Jackson A., Haroon H., Zhu X.P., et al. Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed 2002, 15(2):164-173.
17. Orton M.R., Miyazaki K., Koh D.M., et al. Optimizing functional parameter accuracy for breath-hold DCE-MRI of liver tumours. Phys Med Biol 2009, 54(7):2197-2215.
18. Melbourne A., Atkinson D., White M.J., et al. Registration of dynamic contrast-enhanced MRI using a progressive principal component registration (PPCR). Phys Med Biol 2007, 52(17):5147-5156.
19. Noseworthy M.D., Haider M.A., Sussman M.S., et al. Free-breathing motion compensation using template matching: a technique allowing for tracer kinetic modeling of liver metastases. J Comput Assist Tomogr 2007, 31(2):193-197.
20. Buonaccorsi G.A., Roberts C., Cheung S., et al. Tracer kinetic model-driven registration for dynamic contrast enhanced MRI time series. Med Image Comput Comput Assist Interv 2005, 8(Pt 1):91-98.
21. Miles K.A., Hayball M.P., Dixon A.K. Functional images of hepatic perfusion obtained with dynamic CT. Radiology 1993, 188(2):405-411.
22. Roberts C., Buckley D.L., Parker G.J. Comparison of errors associated with single- and multi-bolus injection protocols in low-temporal-resolution dynamic contrast-enhanced tracer kinetic analysis. Magn Reson Med 2006, 56(3):611-619.
23. Tofts P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997, 7(1):91-101.
24. Liu Y., Matsui O. Changes of intratumoral microvessels and blood perfusion during establishment of hepatic metastases in mice. Radiology 2007, 243(2):386-395.
25. Koh T.S., Thng C.H., Lee P.S., et al. Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. Radiology 2008, 249(1):307-320.
26. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390.
27. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134.
28. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
29. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25(13):1760-1764.
30. van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., et al. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010, 102(5):803-809.
31. Smith A.D., Lieber M.L., Shah S.N. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010, 194(1):157-165.
32. Meijerink M.R., van Cruijsen H., Hoekman K., et al. The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 2007, 17(7):1700-1713.
33. Miyazaki K., Collins D.J., Walker-Samuel S., et al. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 2008, 18(7):1414-1421.
34. Chen G., Ma D.Q., He W., et al. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2008, 14(37):5738-5743.
35. Meijerink M.R., van Waesberghe J.H., van der Weide L., et al. Early detection of local RFA site recurrence using total liver volume perfusion CT initial experience. Acad Radiol 2009, 16(10):1215-1222.
36. Bolton R.P., Mairiang E.O., Parkin A., et al. Dynamic liver scanning in cirrhosis. Nucl Med Commun 1988, 9(3):235-247.
37. Blomley M.J., Coulden R., Dawson P., et al. Liver perfusion studied with ultrafast CT. J Comput Assist Tomogr 1995, 19(3):424-433.
38. Hashimoto K., Murakami T., Dono K., et al. Assessment of the severity of liver disease and fibrotic change: the usefulness of hepatic CT perfusion imaging. Oncol Rep 2006, 16(4):677-683.
39. Annet L., Materne R., Danse E., et al. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003, 229(2):409-414.
40. Van Beers B.E., Leconte I., Materne R., et al. Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. AJR Am J Roentgenol 2001, 176(3):667-673.
41. Hagiwara M., Rusinek H., Lee V.S., et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging-initial experience. Radiology 2008, 246(3):926-934.
42. Sahani D.V., Holalkere N.S., Mueller P.R., et al. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 2007, 243(3):736-743.